R2 Technology's proprietary mammography CAD has been approved by the FDA for sale with Fischer Imaging's SenoScan TrueView digital mammography system. Fischer plans to integrate R2's ImageChecker technology with SenoScan to support CAD analysis of
R2 Technology's proprietary mammography CAD has been approved by the FDA for sale with Fischer Imaging's SenoScan TrueView digital mammography system. Fischer plans to integrate R2's ImageChecker technology with SenoScan to support CAD analysis of digital mammograms.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.